Nifekalant
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in JACC: Case Reports
- Vol. 2 (2) , 235-239
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 8 references indexed in Scilit:
- 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJACC, 2014
- Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillationInternal and Emergency Medicine, 2010
- Report From J-PULSE Multicenter Registry of Patients With Shock-Resistant Out-of-Hospital Cardiac Arrest Treated With Nifekalant HydrochlorideCirculation Journal, 2010
- Mechanisms for the genesis of paroxysmal atrial fibrillation in the Wolff--Parkinson--White syndrome: intrinsic atrial muscle vulnerability vs. electrophysiological properties of the accessory pathwayEP Europace, 2008
- Effect of Nifekalant for Acute Conversion of Atrial Flutter: The Possible Termination Mechanism of Typical Atrial FlutterPacing and Clinical Electrophysiology, 2007
- Atrial fibrillation in the Wolff-Parkinson-White syndrome: ECG recognition and treatment in the EDThe American Journal of Emergency Medicine, 2007
- Effects of Intravenous Nifekalant, A Class III Antiarrhythmic Drug, on Atrial Vulnerability Parameters in Patients with Paroxysmal Atrial FibrillationPacing and Clinical Electrophysiology, 2004
- Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillationAmerican Heart Journal, 1996